CervoMed (NASDAQ:CRVO – Get Free Report) and Rafael (NYSE:RFL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
Institutional & Insider Ownership
25.2% of CervoMed shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 35.8% of CervoMed shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for CervoMed and Rafael, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CervoMed | 1 | 1 | 4 | 1 | 2.71 |
| Rafael | 1 | 0 | 0 | 0 | 1.00 |
CervoMed presently has a consensus target price of $21.00, indicating a potential upside of 809.09%. Given CervoMed’s stronger consensus rating and higher possible upside, equities analysts plainly believe CervoMed is more favorable than Rafael.
Profitability
This table compares CervoMed and Rafael’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CervoMed | N/A | -156.02% | -128.34% |
| Rafael | -3,321.74% | -41.27% | -35.32% |
Risk & Volatility
CervoMed has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500. Comparatively, Rafael has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.
Valuation and Earnings
This table compares CervoMed and Rafael”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CervoMed | $4.01 million | 8.71 | -$26.97 million | ($3.22) | -0.72 |
| Rafael | $920,000.00 | 73.20 | -$30.52 million | ($0.68) | -1.90 |
CervoMed has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.
Summary
CervoMed beats Rafael on 10 of the 15 factors compared between the two stocks.
About CervoMed
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
About Rafael
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
